Medroxyprogesterone acetate and Estradiol cypionate injection |
Lunelle |
Clinical Trial: Phase 3 Study to evaluate Anecortave Acetate vs. Visudyne for the treatment of the wet form of AMD.
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Macular Degeneration | Drug: Anecortave Acetate | Phase III |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Location Information
Texas
US, Canada, Australia and Europe, Ft. Worth, Texas, United States
More Information
Click here for more information about this study: A Phase III Clinical Trial for AMD: Information for Potential Participants
Record last reviewed: September 2003
Last Updated: October 13, 2004
Record first received: July 9, 2002
ClinicalTrials.gov Identifier: NCT00041483
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Lunelle (Drug Digest)
- Medroxyprogesterone acetate and Estradiol cypionate injection (Drug Digest)

Not Signed In -


